BioMarin says VOXZOGO lifts height SDS 0.72 over three years in hypochondroplasia study at ENDO 2026

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

BMRN

0.00
  • BioMarin highlighted new VOXZOGO data in hypochondroplasia, presented at ENDO 2026, showing sustained growth benefits over three years with a favorable safety profile.
  • The update supports plans to file a U.S. supplemental NDA for VOXZOGO in hypochondroplasia in Q3 2026, following positive Phase 3 topline results.
  • Phase 1 results for investigational BMN 333, also presented at ENDO 2026, supported the potential for weekly dosing in achondroplasia with tolerable safety.
  • Enrollment has started in a registration-enabling Phase 2/3 study for BMN 333; a dose-finding update is expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606160905PR_NEWS_USPR_____SF83044) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.